Skip to content
    ALHC
    Earnings call· Jun 2026(Q2 FY26)

    Alignment Healthcare Q2 FY26 earnings call ALHC

    Jul 30, 2026 Source

    Executive summary

    Alignment Healthcare Q2 FY26 — Strong Performance Driven by Membership Growth and Margin Expansion

    Alignment Healthcare delivered a strong second quarter, driven by robust membership growth and significant margin expansion, achieving its lowest MBR as a public company. The company is on track to meet its full-year profitability targets, supported by its Care Anywhere clinical model and AI-powered stratification. Management is strategically increasing investments in clinical innovation, AI, and talent in the second half of the year to drive future operating leverage and prepare for new market growth, balancing near-term profitability with long-term scalability and embedded earnings potential.

    Highlights

    5

    • Health plan membership grew approximately 31% year-over-year to 294,100 members.

    • Total revenue increased 32% year-over-year to $1.3 billion.

    • Adjusted MBR improved by 40 basis points year-over-year to 86.3%, marking the lowest MBR as a public company.

    • Adjusted EBITDA grew 48% year-over-year to $68 million, with a 5.1% margin, representing 60 basis points of expansion.

    • First half adjusted EBITDA increased 60% versus prior year to $106 million, on track for full-year guidance.

    Concerns

    2

    • Q3 FY26 adjusted EBITDA guidance of $20 million to $30 million reflects increased investments in clinical operations and SG&A, leading to a seasonally higher MBR compared to prior year.

    • Unfavorable prior year development of approximately $6 million was recorded in Q2 FY26 to bolster reserves.

    Guidance & targets

    12
    CategoryTargetConfidence
    Full-year 2026 Adjusted EBITDA
    $154 million at the midpoint
    high materiality
    High
    Full-year 2026 Adjusted Gross Profit
    $640 million at the midpoint
    high materiality
    High
    Full-year 2026 Health Plan Membership
    298,000 and 301,000 members
    high materiality
    High
    Full-year 2026 Revenue
    $5.20 billion to $5.23 billion
    high materiality
    High
    Full-year 2026 Adjusted Gross Profit
    $630 million and $650 million
    high materiality
    High
    Full-year 2026 Adjusted EBITDA
    $145 million to $163 million
    high materiality
    High
    Q3 2026 Health Plan Membership
    295,500 and 297,500 members
    medium materiality
    High
    Q3 2026 Revenue
    $1.30 billion to $1.32 billion
    medium materiality
    High
    Q3 2026 Adjusted Gross Profit
    $148 million and $158 million
    medium materiality
    High
    Q3 2026 Adjusted EBITDA
    $20 million to $30 million
    high materiality
    High
    Full-year Adjusted EBITDA Contribution from Second Half
    approximately 30%
    medium materiality
    High
    2027 Enrollment Growth
    20%
    high materiality
    High

    Operational metrics

    18
    Health plan membership
    294,10031% year-over-year growth
    Q2 FY26

    Supported by strong new member additions and high retention.

    Total revenue
    $1.3 billion32% growth year-over-year
    Q2 FY26

    Driven by health plan membership growth.

    Adjusted gross profit
    $183 million
    Q2 FY26

    Represented an adjusted MBR of 86.3%.

    Adjusted SG&A
    $115 millionincreased 29% year-over-year
    Q2 FY26

    As a percentage of revenue, it was 8.6%.

    Adjusted SG&A as percentage of revenue
    8.6%improved 20 basis points year-over-year
    Q2 FY26

    Outperformed midpoint of implied guidance range by 40 basis points.

    Adjusted EBITDA
    $68 milliongrew by 48% year-over-year
    Q2 FY26

    Produced an adjusted EBITDA margin of 5.1%.

    Adjusted EBITDA margin
    5.1%60 basis points of margin expansion year-over-year
    Q2 FY26

    Resulted from strong Q2 performance.

    First half adjusted EBITDA
    $106 millionincrease of 60% versus the prior year
    H1 FY26

    On track for full year guidance.

    First half adjusted SG&A as percentage of revenue
    8.7%improved 40 basis points year-over-year
    H1 FY26

    Demonstrates efficiency of operating model and improving unit economics.

    Embedded gross profit potential (current membership)
    $880 million
    current

    Positions the company to deliver further earnings growth from existing members.

    Embedded gross profit potential (early 2025)
    $600 million
    early 2025

    Total opportunity indicated when first shared.

    Cash, cash equivalents and short-term investments
    $702 million
    Q2 FY26 end

    Reflects strong liquidity profile.

    Prior year development
    $6 millionunfavorable
    Q2 FY26

    Bolstered reserves by this amount, related to 2025 claims development. Year-to-date favorable by $2 million.

    Underlying Q2 MLR (analyst estimate)
    86.2%
    Q2 FY26

    Analyst's calculation excluding unfavorable development and suite benefit, confirmed by management as 'net around the same level'.

    Long-term MBR (JPMorgan deck)
    93%
    Year 1

    Referenced from a 2025 JPMorgan deck for cohort tracking.

    Long-term MBR (JPMorgan deck)
    82.1%
    Year 5

    Referenced from a 2025 JPMorgan deck for cohort tracking.

    New member mix in acute categories
    50%
    FY26

    Intentional strategy, leading to a slightly elevated initial MLR but expected to be favorable over time.

    Final suite pickup
    $6 million
    Q2 FY26

    Related to new members for 2025, smaller than prior year due to V28 impact and member mix.

    Industry KPIs

    6
    MetricValueDetails
    Utilization trendsmid-150sadmissions per 1,000
    Stars rate environmentmeaningful upward drift
    Medical loss care ratio86.3%%
    Membership covered lives by line294,100members
    Adjusted EPS EBITDA leverage guidance$68 millionUSD
    Medical cost trend vs pricing assumptiontracking closely to expectations

    Risks & headwinds

    5
    Increased Investments Impacting Q3 ProfitabilityQ3 FY26

    Additional double-digit million across clinical and SG&A categories, weighting higher in Q3. Q3 Adjusted EBITDA guidance of $20 million to $30 million.

    Mitigation: Investments are deliberate and within full-year financial commitments, designed to drive future operating leverage and returns in 2027 and beyond. Reinvesting savings into automation, AI, new market expansions, and branding.

    Seasonality Shift in Adjusted EBITDA ContributionH2 FY26

    Approximately 30% of full year adjusted EBITDA expected in H2 FY26, compared to 40% in H2 of prior year.

    Mitigation: Driven by a flatter slope to Part D MBR and planned investments. Management is taking a prudent approach to utilization assumptions for the remaining year.

    Higher Acuity in New Member MixFY26

    50% of new members in C-SNP, D-SNP, or Dual-Eligible categories, leading to a slightly elevated initial MBR.

    Mitigation: This is an intentional investment, as the care model is tailor-made for these populations, with an expectation of achieving favorable MLRs over time by improving member health and reducing costs.

    Unfavorable Prior Year DevelopmentQ2 FY26

    $6 million unfavorable prior year development in Q2 FY26.

    Mitigation: This was a proactive decision to bolster reserves for 2025 claims, reflecting a prudent approach to reserve positioning. Year-to-date, prior year development is favorable by $2 million.

    Uncertainty in Stars Regulatory EnvironmentFuture (2028 Stars)

    Meaningful upward drift in Stars cut points in recent years. CMS technical rule for 2028 Stars is under review at OMB.

    Mitigation: Management is comfortable with their position and is monitoring the regulatory and legal landscape, noting that the footing surrounding Stars is 'shaky' and outcomes could differ based on implementation of regulatory changes.

    What to watch in Q3 FY26

    5

    Q3 Adjusted EBITDA Performance

    next quarter
    CurrentQ3 FY26 guidance: $20M-$30M
    TargetPerformance relative to guidance, impact of investments

    Why it matters

    Q3 guidance is lower than prior quarters due to strategic investments; verifying its outcome will indicate the effectiveness of these investments and their impact on near-term profitability.

    For the third quarter, we expect health plan membership to be between 295,500 and 297,500 members, revenue to be in the range of $1.30 billion to $1.32 billion, adjusted gross profit to be between $148 million and $158 million and adjusted EBITDA to be in the range of $20 million to $30 million.

    Q&A highlights

    7

    Can you provide more detail on the Q3 guide, the timing and nature of the investments, and their expected benefits in the back half of 2026 and into 2027/2028?

    Management explained Q3 guidance reflects seasonality (new member mix, Part D) and strategic investments. These investments, totaling double-digit millions across clinical operations (Care Anywhere, new market prep) and SG&A (automation, AI), are deliberate and designed to yield returns in 2027 and beyond, positioning the company for long-term opportunity.

    “It could be in the second half, an additional double-digit million across clinical and SG&A categories with the weighting of some of that being a little bit higher in Q3. okay? But this was all very deliberate. And it's inside the financial commitments we're making for 2026.”

    asked by Ryan Daniels · answered by James Head

    2 min read6 chapters

    Detailed Narrative

    01

    AI-Powered Clinical Model Enhancements

    Alignment Healthcare has deployed the newest version of its AVA AI-powered stratification model, significantly improving its ability to predict hospitalizations. The model now accurately predicts the 10% of members who account for nearly 70% of hospital admissions over the next 30 days. This innovation, along with disease state registries, supports the proactive engagement activities of the Care Anywhere clinical teams, reinforcing the company's focus on managing polychronic populations.

    02

    Embedded Earnings Potential from Membership Cohorts

    Approximately 50% of Alignment Healthcare's current members are in their first or second year, indicating substantial embedded earnings potential. The embedded gross profit potential of today's membership has grown to approximately $880 million, up from $600 million in early 2025. This positions the company for further earnings growth from existing members as they are engaged through clinical programs and mature within the system, with future membership growth further expanding this potential.

    03

    Strategic Investments for Scalability and Future Growth

    The company is making thoughtful investments in core systems, cross-functional workflows, and talent to strengthen the durability and scalability of its MA platform. These include implementing a more scalable human resources platform, clinical EHR capabilities, and enhanced claims processing systems. Looking ahead, investments will focus on automation of back-office processes, new market expansions, branding initiatives, and deepening AI capabilities, with a portion of savings reinvested to drive future operating leverage and tangible returns.

    04

    Q3 Seasonality and Investment Impact

    The Q3 FY26 guidance reflects a change in seasonality, with approximately 30% of full-year adjusted EBITDA expected in the second half, compared to 40% in the prior year. This shift is attributed to a flatter slope in Part D MBR, a new member mix with higher acuity, and planned investments in clinical operations (Care Anywhere) and SG&A. These investments, estimated in the double-digit millions, are aimed at preparing for new market growth and 2027 launches, leading to a seasonally higher MBR and SG&A expenses in Q3.

    05

    California vs. Non-California Market Performance

    Management noted that the mature California market is performing well, while non-California markets have seen substantial growth over the last two years. The company expects MLRs in ex-California states to improve as member cohorts mature, similar to the embedded value observed in California. The operational focus is not on statutory filings as a proxy for business, but on overall performance tracking to expectations across both regions.

    06

    2027 Bidding Strategy and Industry Outlook

    While specific 2027 bidding strategies were not disclosed for competitive reasons, management expressed strong confidence in their overall product strategy, emphasizing scale and portability. They anticipate a mixed approach from the industry, with some competitors, who have been less aggressive recently, potentially becoming more aggressive in 2027 due to market chatter. The company's investments are designed to support expected growth in 2027 and future state expansions in 2028.

    AI-generated summary of the company’s earnings call. Not investment advice.